Screener
Allogene Therapeutics ALLO Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of property and equipment | (9) | (99) |
| Proceeds from maturities of investments | 72,115 | 56,500 |
| Purchase of investments | (101,694) | (50,225) |
| Net cash provided by (used in) investing activities | (29,588) | 6,176 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs | 20,668 | 10,002 |
| Proceeds from CIRM award (Note 5) | — | 3,350 |
| Proceeds from issuance of common stock upon exercise of stock options | 4 | — |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's investing cash flow?
- Allogene Therapeutics (ALLO) reported investing cash flow of -$29.59M in Q1 2026.
- How has Allogene Therapeutics's investing cash flow changed year-over-year?
- Allogene Therapeutics's investing cash flow decreased by 579.1% year-over-year, from $6.18M to -$29.59M.
- What is the long-term trend for Allogene Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Allogene Therapeutics's investing cash flow has grown at a -23.6% compound annual growth rate (CAGR), from $163.66M to $95.56M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Allogene Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude